Working… Menu
Trial record 27 of 88 for:    "Neuromuscular Disease" | "Norepinephrine"

Study of Fibromyalgia Treated With Milnacipran

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01125423
Recruitment Status : Unknown
Verified December 2010 by Albany Medical College.
Recruitment status was:  Recruiting
First Posted : May 18, 2010
Last Update Posted : June 27, 2011
Forest Laboratories
Information provided by:
Albany Medical College

Brief Summary:

The purpose of this study is to examine the characteristics of the nerves and the small veins in the skin of people with fibromyalgia. This information will then be used to identify possible processes in the skin that may help explain why some people feel pain relief with the study drug (milnacipran) and others do not. The investigators expect to learn more about the pathophysiology of fibromyalgia and the way in which milnacipran acts on these patients. The investigators hypotheses are:

  1. The pathophysiologic basis of fibromyalgia in some patients may be due to a biochemical and/or morphological pathology among the sensory innervation.
  2. Fibromyalgia patients may have different sites of innervation.
  3. Milnacipran may have a therapeutic effect on some fibromyalgia patients.
  4. Abnormalities in fibromyalgia patients may predict the likelihood of a good response to milnacipran.

Condition or disease Intervention/treatment Phase
Fibromyalgia Drug: Milnacipran Procedure: Skin biopsy Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Pilot Study to Assess Potential Mechanisms for Fibromyalgia in Peripheral Tissue Innervation That Could Predict Therapeutic Responsiveness to Milnacipran
Study Start Date : May 2010
Estimated Primary Completion Date : May 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Fibromyalgia

Intervention Details:
  • Drug: Milnacipran
    Subject will then be titrated onto milnacipran over 8 days to subject reported optimal pain control or a maximal dose of 100mg/day per package insert. Subjects will be permitted to increase or decrease their dosing at any time during the study per MD discretion in order to maintain optimal pain control.
    Other Name: Savella
  • Procedure: Skin biopsy
    3 mm skin biopsies will be obtained from the dominant trapezius and the glabrous hypothenar area of the hand.

Primary Outcome Measures :
  1. Efficacy of milnacipran will be determined by neurological and pain assessments [ Time Frame: 10 weeks ]
    Patients will be evaluated prior to being started on milnacipran and again after 8 weeks. We will use data from VAS scores, sleep diaries and quantative sensory testing.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Female age 18-70
  • fulfill the ACR criteria for FMA (wide spread pain for a least 3 months and pain in at least 11 or 18 tender point sites.
  • VAS score greater that 40mm at Screening and Randomization visits.

Exclusion Criteria:

  • History of clinically significant liver disease, serious peripheral vascular disease, a blood clotting disorder, or any other medical condition felt to be exclusionary by the investigator.
  • Allergy to lidocaine
  • Unwillingness to sign informed consent or any other reasons for which the investigator feels the subject cannot complete the study
  • Women who are pregnant, breastfeeding or trying to become pregnant
  • Active cancer with the previous two years except treated basal cell carcinoma of the skin.
  • presence of dermatological or neurological condition that could interfere with the interpretation of the skin biopsy or QST
  • Co-existing conditions that can produce chronic widespread pain
  • Presence of uncontrolled or severe depression
  • Patients with Worker's Compensation, pending Worker's Compensation,
  • any ongoing litigation or disability claims due to fibromyalgia or any other source of pain, or currently receiving monetary compensation as a result of any of the above.
  • presence of uncontrolled narrow-angle glaucoma

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01125423

Layout table for location contacts
Contact: Charles E. Argoff, MD 518 262 6538

Layout table for location information
United States, New York
Upstate Clinical Research, LLC Recruiting
Albany, New York, United States, 12205
Contact: Suzanne Alterman, RN    518-533-1500   
Principal Investigator: James Wymer, MD         
Sponsors and Collaborators
Albany Medical College
Forest Laboratories
Layout table for investigator information
Principal Investigator: Charles E. Argoff, MD Neurosciences Institute, Albany Medical College

Layout table for additonal information
Responsible Party: Charles Argoff, MD, Neurosciences Institute, Albany Medical College Identifier: NCT01125423     History of Changes
Other Study ID Numbers: MIL2009-FFMS
First Posted: May 18, 2010    Key Record Dates
Last Update Posted: June 27, 2011
Last Verified: December 2010
Keywords provided by Albany Medical College:
age 18 to 70
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuromuscular Diseases
Serotonin and Noradrenaline Reuptake Inhibitors
Myofascial Pain Syndromes
Muscular Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Nervous System Diseases
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Physiological Effects of Drugs
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Antidepressive Agents
Psychotropic Drugs